BiotechTube

JYNNEOS (Liquid Formulation) + JYNNEOS (Lyophilized Formulation)

Phase 3Active
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Monkeypox Virus Infection

Conditions

Monkeypox Virus Infection

Trial Timeline

Feb 23, 2017 → Dec 31, 2025

NCT ID
NCT02977715

About JYNNEOS (Liquid Formulation) + JYNNEOS (Lyophilized Formulation)

JYNNEOS (Liquid Formulation) + JYNNEOS (Lyophilized Formulation) is a phase 3 stage product being developed by Bavarian Nordic for Monkeypox Virus Infection. The current trial status is active. This product is registered under clinical trial identifier NCT02977715. Target conditions include Monkeypox Virus Infection.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02977715Phase 3Active

Competing Products

5 competing products in Monkeypox Virus Infection

See all competitors
ProductCompanyStageHype Score
BNT166aBioNTechPhase 1/2
38
BNT166aBioNTechPhase 2
49
MVA-BNBavarian NordicPhase 2
49
MVA-BN standard regimen + MVA-BN half-dose regimenBavarian NordicPhase 3
74
Jynneos + MVA-BN (Quail)Bavarian NordicPhase 2
49

Other Products from Bavarian Nordic

IMVAMUNE®Approved
82
VAXCHORA (Cholera Vaccine, Live, Oral)Approved
82
PROSTVAC-V + PROSTVAC-F + GM-CSF + PlaceboPhase 3
74
PXVX0200 + placeboPhase 3
74
MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP)Phase 3
74